CLINICAL TRIAL: ANTIRETROVIRAL ACTIVITY OF RALTEGRAVIR IN HIV-1 INFECTED CHILDRE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目标： 1.评估在最初稳定的背景疗法基础上加用雷替格列韦治疗HIV-1的短期安全性耐受性。 2.评价在稳定背景疗法中加入雷替格雷的稳态血药浓度曲线和药代动力学参数。 3.评价选定剂量的雷替格列韦与优化的本底治疗相结合的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: 1. to evaluate the short term safety tolerability of raltegravir added to an initial stable background therapy in HIV-1 2. to evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of raltgravir added to the stable background therapy 3. to evaluate the safety and tolerability of raltegravir at the selkected dose in combination with optimized background therapy